Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 103 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrOXGExNTFyIN88US=> MmnvNE01KGR? NY\HSnhxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlroNlY4ODJ5OES=
HepG2 M1jh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[2NVAuOTBizszN MlLCNE01KGR? NYnXd|d5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUDyb45POjZ5MEK3PFQ>
HT29 M1vTd2Z2dmO2aX;uJGF{e2G7 NVjwWYZ[PTEEoH7N MofwNlQuPzJiaB?= NYfGNolHcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh Mnz2NlY4ODJ5OES=
HepG2 NXPrNVNYTnWwY4Tpc44hSXO|YYm= NVL0SWNJPTEEoH7N MYOyOE04OiCq NFrCPJZqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> MmHtNlY4ODJ5OES=
HCC827 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPHOU84NjVxMUCgcm0> NGDmNVE4OsLiaB?= NXfEb2N1TE2VTx?= MlPO[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? MnjNNlY3PzV2OES=
A549  M3fXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxNE8yPS9{MDDuUS=> NFe4VJc4OsLiaB?= NWLKOZNRTE2VTx?= NWnxXm9w\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NFjqTpozPjZ5NUS4OC=>
NCI-H460  M1n0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNE8zOC9|MDDuUS=> MkDaO|LDqGh? NXThU5U6TE2VTx?= M{jDNoVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk M2rvelI3Pjd3NEi0
J89GFP MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S0XmROW00EoB?= NVr5dYl1TUN3ME20PU45PSEEsTCxNk43PSCwTR?= MVWyOlU3OzV4OB?=
THP89GFP M2Hxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoeySG1UV8Li MmWwSWM2OD1zOT6zOEDDuSB4LkSzJI5O MVSyOlU3OzV4OB?=
SK-NEP-1 NWXLPWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrBVGhOOC5yMfMAl|ExNjBizszN NWDscpU2OjRiaB?= M3;kRWROW00EoB?= MmWwTWM2OD15Nj6zOEBvVQ>? NU\jbpBZOjZzN{[yNVk>
G401 NInUSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMlAy6oDVMUCuNEDPxE1? M3j1VVI1KGh? MVLEUXNQyqB? MWPJR|UxRTF2Mz6wNkBvVQ>? MWSyOlE4PjJzOR?=
SK-NEP-1 NEHWR2xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUm1NEBvVQ>? M3rHRVHjiJN2IHS= MmPQSG1UV8Li NYj0T3JmemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NUPVXohROjZzN{[yNVk>
G401 NHPzXGxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFrtUG42OCCwTR?= M1jiZ|HjiJN2IHS= NFKzS2JFVVORwrC= M4LWcZJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NXnDTpJYOjZzN{[yNVk>
SK-NEP-1 NEHJcXNCeG:ydH;zbZMhSXO|YYm= MXm1NE8yODBibl2= M2HwdlI1KGh? NIfuT3pFVVORwrC= MYjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4jzZVI3OTd4MkG5
G401 Mon3RZBweHSxc3nzJGF{e2G7 MoDrOVAwOTByIH7N MWWyOEBp MoH1SG1UV8Li M1;FcYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{\he|I3OTd4MkG5
SK-NEP-1 Ml\vSpVv[3Srb36gRZN{[Xl? NUfLNXJoPTBxMUCwJI5O Mof5NlQhcA>? MoLZSG1UV8Li M3X6TJNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? M3LpdlI3OTd4MkG5
G401 MX7GeY5kfGmxbjDBd5NigQ>? NIDScZE2OC9zMECgcm0> MYOyOEBp MlLZSG1UV8Li MlXRd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? NGLMcZYzPjF5NkKxPS=>
SK-NEP-1 MWXGeY5kfGmxbjDBd5NigQ>? NELVVlA2OC9zMECgcm0> MmXaNlQhcA>? MX7EUXNQyqB? NILsd|lqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? NV7FfI1TOjZzN{[yNVk>
G401 MVnGeY5kfGmxbjDBd5NigQ>? NWnPcY9rPTBxMUCwJI5O M3;EfFI1KGh? M{LxVWROW00EoB?= NVrwU2VjcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M{LQdlI3OTd4MkG5
RPMI 8226 NEXyemNE\WyuIGP1dpZqfmGuIFHzd4F6 MWCyM|QwPiCwTR?= NXeyXWZwPDkkgJno NHP0VINqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NIDKZmQzPjByMEK5Ni=>
OPM2 M{nxNmNmdGxiU4Xyeol3[WxiQYPzZZk> Mn\QNk81NzZibl2= M1nNbVQ56oDLaB?= MYXpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp M2HGd|I3ODByMkmy
U266 NWjFdoNkS2WubDDTeZJ3cX[jbDDBd5NigQ>? NITHXY0zNzRxNjDuUS=> Mm[2OFjjiImq NWq5UZJMcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MWGyOlAxODJ7Mh?=
H929 MlTSR4VtdCCVdYL2bZZidCCDc4PhfS=> NFvPWmszNzRxNjDuUS=> M2\v[FQ56oDLaB?= M1jq[Ylv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? M2C1flI3ODByMkmy
RPMI 8226  M4GyT2Fxd3C2b4Ppd{BCe3OjeR?= MXy05qCKdk1? NF7zbnczPC92ODDo MnHEbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NXroVVdlOjZyMECyPVI>
HCC827 M{DjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jqdFExKG6P MkPNOFghcA>? M{n6UmROW09? NV;2bnFs\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MmTvNlU6PDR4MUe=
NCI-H23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLXcpEyOCCwTR?= MlrhOFghcA>? NIPC[4ZFVVOR NHP0[XRmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= M1\3elI2QTR2NkG3
AML3 MknYSpVv[3Srb36gRZN{[Xl? MX:wMVEh|ryP NWPWOWdJOjUEoHi= M2S0dIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEXTVnQzPTZzMkm0NS=>
ML-1 NFGyTFlHfW6ldHnvckBCe3OjeR?= MXSwMVEh|ryP MV6yOOKhcA>? NGnPZW1qdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWPRPIxROjV4MUK5OFE>
RPMI-8226vr10  NWPOZ3k6TnWwY4Tpc44hSXO|YYm= MoTqNE0yKM7:TR?= MV2yOOKhcA>? NYfD[|N5cW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3vGVVI2PjF{OUSx
ML-1 NWrnSnJUTnWwY4Tpc44hSXO|YYm= MXyxJO69VQ>? NV6wWFVzOjUEoHi= NFy4VJZqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=> MUCyOVYyOjl2MR?=
RPMI-8226vr10  NYHaeIg2TnWwY4Tpc44hSXO|YYm= NHyzdYgyKM7:TR?= NW\qTHhoOjUEoHi= MWnpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk MlLONlU3OTJ7NEG=
SK-N-BE (2) M334b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoNGkzPOLCiXi= NUXUfZk4UUN3ME2xNFQvOOLCidMx5qCKPy56IH7N MYOyOVMxQDlzNh?=
SK-N-BE (2), PAN  MK MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKyNlTjiImq NEnJc49KSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= MX[yOVMxQDlzNh?=
SK-N-BE (2), MK  PAN NGr4[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPxNlTjiImq MoLwTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= M2DCTlI2OzB6OUG2
SK-N-AS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrUXnMzPOLCiXi= NIfCSllKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= MkXxNlU{ODh7MU[=
SK-N-DZ NV20RpdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnYe2R[OjUkgJno NUDZWmdGUUN3ME2xO{4y6oDLwsJihKkxNjRibl2= M4jCNFI2OzB6OUG2
Caki-1 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmezNVAwOjVxNUCgcm0> M1TkSlQ5KGh? MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MWKyOVI4QTF7MR?=
ACHN NH7F[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxNE8zPS93MDDuUS=> NF3XSm81QCCq MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NV62Oo9iOjV{N{mxPVE>
769-P MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNE8zPS93MDDuUS=> NWL3UIlWPDhiaB?= M2q3b4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M1iwclI2Ojd7MUmx
786-O  NID6T4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITjNXIyOC9{NT:1NEBvVQ>? NU\kZ5Q3PDhiaB?= NETVcVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MmfENlUzPzlzOUG=
Caki-1 Ml\nRZBweHSxc3nzJGF{e2G7 NVTRbY1XPTBibl2= MV20PEBp M323c4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ MVqyOVI4QTF7MR?=
ACHN NIH6OZRCeG:ydH;zbZMhSXO|YYm= M{jI[FUxKG6P NEHXfnQ1QCCq M3PWUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ M1;pVlI2Ojd7MUmx
769-P NWK0bmlSSXCxcITvd4l{KEG|c3H5 M1LLOlUxKG6P MnmwOFghcA>? MkX6bY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Mn3HNlUzPzlzOUG=
786-O  M1rZVWFxd3C2b4Ppd{BCe3OjeR?= MXu1NEBvVQ>? NFK1fYk1QCCq M3\sTIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ MkX5NlUzPzlzOUG=
Caki-1 NX6ycG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TiT|I2NzVyIH7N NFvBWFc1QCCq M4rPbmROW09? NHzob25qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NVPOb3dtOjVzN{[zOVQ>
ACHN MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXMNlUwPTBibl2= NV3y[Gx3PDhiaB?= NWPIUFJDTE2VTx?= M{\QcYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NVfDOItIOjVzN{[zOVQ>
769-P MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTrNlUwPTBibl2= MnfCOFghcA>? M4nSXWROW09? M3TSXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NXjvRo9GOjVzN{[zOVQ>
Caki-1 MWHDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MnjJOVAhdk1? M3LiW|cuOTRiZB?= M{jF[WROW09? Mlvpd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MlnxNlUyPzZ|NUS=
ACHN NFfp[INEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NEfpWXM2OCCwTR?= MUe3MVE1KGR? MYLEUXNQ MVvzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> M3\mOlI2OTd4M{W0
769-P M2fGXWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MkPQOVAhdk1? NWiyZ|k6Py1zNDDk M1O1OWROW09? Mmj6d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MojwNlUyPzZ|NUS=
Caki-1 NF[zTo1CeG:ydH;zbZMhSXO|YYm= NWnWSXFOPTBibl2= NGnpPYo1QCCq NF25TGRFVVOR M3PxUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYHqNXhEOjVzN{[zOVQ>
ACHN M2THb2Fxd3C2b4Ppd{BCe3OjeR?= M3y0V|UxKG6P M4fifVQ5KGh? Ml\kSG1UVw>? MlPqbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NI\PWHozPTF5NkO1OC=>
769-P MXPBdI9xfG:|aYOgRZN{[Xl? MkjTOVAhdk1? NHLG[2I1QCCq MnLoSG1UVw>? NF;yXFNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NELJ[5UzPTF5NkO1OC=>
MDA-MB-231 M2PLbm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NHnLNnkyOMLibl2= MoS0N:Kh\A>? NWrXW5N5TE2VTx?= Mn[4ZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NGPhfpEzPDhzMES5Oy=>
BT-549 NWLn[G1nVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MXqxNOKhdk1? MVizxsBl MWXEUXNQ MkTEZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi M4nZOlI1QDFyNEm3
MCF-7  M17ZZm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? M4SwflExyqCwTR?= M4jtOVPDqGR? NGrBXFJFVVOR MnTjZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi Ml7ENlQ5OTB2OUe=
MCF-7 M4DnWWZ2dmO2aX;uJGF{e2G7 M13NWVUuPTBibl2= M3PsbVI1KGh? NUj4W|BKTE2VTx?= M3TyZ5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MYqyOFM3PjRyNx?=
CTS NYKzTIY3SXCxcITvd4l{KEG|c3H5 MYiw5qCUPDBibl5CpC=> NVf5Tmk6PDhiaB?= NFvpd2pqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{LJS|I1OjR2NEK5
OCI-AML3  NXqzPVhGSXCxcITvd4l{KEG|c3H5 MoHlNQKBmzRyIH7NxsA> MXu0PEBp NXP2OXNNcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mm\pNlQzPDR2Mkm=
U937 NWriRZRRSXCxcITvd4l{KEG|c3H5 NHnLSJIx6oDVNECgcm3DqA>? NGG5TGQ1QCCq M1O4cYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV\sVGxCOjR{NES0Nlk>
PC3 NYTudJB2SXCxcITvd4l{KEG|c3H5 MlPVNE0yODBibl2= NGnIenMzPC92ODDo NVr6cWkxcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnPSNlQyPjN{M{C=
PC3-AR MXPBdI9xfG:|aYOgRZN{[Xl? NE\jVmwxNTFyMDDuUS=> M{DSbFI1NzR6IHi= NUfkRYF6cW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn7YNlQyPjN{M{C=
PC3 M37qW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknHNE0yODBibl2= MmS1NlQwPDhiaB?= MknSbY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS|EheG:ydXzheIlwdg>? NVPZN4o3OjRzNkOyN|A>
PC3-AR M1jremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMVExOCCwTR?= MoC5NlQwPDhiaB?= M4LVNIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= NFrpeZUzPDF4M{KzNC=>
PC3 NX;VfIl[TnWwY4Tpc44hSXO|YYm= MV[wMVExOCCwTR?= NH3QPHczPCCq NG\lU5V{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> M1fyU|I1OTZ|MkOw
PC3-AR M3naT2Z2dmO2aX;uJGF{e2G7 NF[2[VcxNTFyMDDuUS=> NX71d2Z6OjRiaB?= NYHKW2x7e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> M2D2eVI1OTZ|MkOw
OS-RC-2 NUPCXolHS2WubDDWbYFjcWyrdImgRZN{[Xl? NUfGTIVLOC1zMECwJI5O NWnwTVl2OjRxNEivO|IhcA>? NYLNZZdsTE2VTx?= NUHofWpF\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MonsNlQyPDR5M{e=
OS-RC-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLoOVAhdk1? NFHpSJE1QCCq MoXBSG1UVw>? MmHFbY5lfWOnczDHNk9OKGG{cnXzeC=> NVzsfnFpOjRzNES3N|c>
OS-RC-2 M3yyXGFxd3C2b4Ppd{BCe3OjeR?= MlHWOVAhdk1? MnrYOFghcA>? MVPEUXNQ MYrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWSyOFE1PDd|Nx?=
SK-N-AS NIXLfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHqb|Ux6oDVOECgcm0> MVu0PEBp NVHRbpZKUUN3ME2yO{41KG6P MXOyOFA6QDd7OR?=
SK-N-DZ NVizNlQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzPNQKBmzhyIH7N M3HqXVQ5KGh? MUnJR|UxRTJzLkmgcm0> MYeyOFA6QDd7OR?=
SK-N-SH MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\KNQKBmzhyIH7N NYH4c2U4PDhiaB?= M2\oT2lEPTB;N{KuN{BvVQ>? Mk\5NlQxQTh5OUm=
SK-N-BE NFXNVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXwe4JVOOLCk{iwJI5O M1;Pc|Q5KGh? MV;JR|UxRTd3LkSgcm0> MXeyOFA6QDd7OR?=
SK-N-AS MofoRZBweHSxc3nzJGF{e2G7 NVTIS5F4OOLCk{iwJI5O M2j3e|Q5KGh? M2HmRpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MljsNlQxQTh5OUm=
SK-N-DZ MkLXRZBweHSxc3nzJGF{e2G7 MnrwNQKBmzhyIH7N M1vBbFQ5KGh? M1nTWJBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NX\xbGJCOjRyOUi3PVk>
SK-N-SH M3;5fGFxd3C2b4Ppd{BCe3OjeR?= MVyw5qCUPDBibl2= MoDjOFghcA>? NVvGdHVXeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v M2n0RlI1ODl6N{m5
SK-N-BE NIO2e25CeG:ydH;zbZMhSXO|YYm= NYHocGx3OOLCk{SwJI5O MnmxOFghcA>? NE[4Tmdxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MXWyOFA6QDd7OR?=
SK-N-AS NU\2ZYFITnWwY4Tpc44hSXO|YYm= MY[w5qCUQDBibl2= MoPGOFghcA>? MWHpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MYmyOFA6QDd7OR?=
SK-N-DZ MV7GeY5kfGmxbjDBd5NigQ>? M1zEPVDjiJN6MDDuUS=> NGS0SZg1QCCq NIrr[mxqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NIP1TZYzPDB7OEe5PS=>
SK-N-SH NWPuT2k{TnWwY4Tpc44hSXO|YYm= MoD3NQKBmzRyIH7N MkDtOFghcA>? M{OybIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MWqyOFA6QDd7OR?=
SK-N-BE M{jQXWZ2dmO2aX;uJGF{e2G7 M{G3T|DjiJN2MDDuUS=> MYC0PEBp M3LhRYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NFz3TXQzPDB7OEe5PS=>
HCC-LM3 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHM[pMyNTFyMECgcm0> NX3DVWlvOjRxNEivO|IhcA>? NVTPVHRvTE2VTx?= NILKWmJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXqyOFA6Ozl3Nh?=
HepG2 NVzlOHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vrOFEuOTByMDDuUS=> MXuyOE81QC95MjDo MUjEUXNQ NYXKd5FxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnvzNlQxQTN7NU[=
SMMC-7721 M{HsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fMU|EuOTByMDDuUS=> NUHlemFZOjRxNEivO|IhcA>? MWjEUXNQ NHrYN4FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFjse4szPDB7M{m1Oi=>
HCC-LM3 M1fJUmFxd3C2b4Ppd{BCe3OjeR?= M2XlXFUxKG6P M{XmdFQ5KGh? NUOwXnZVTE2VTx?= NGPUd3RqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NH7PUIszPDB7M{m1Oi=>
HepG2 NETt[YtCeG:ydH;zbZMhSXO|YYm= NVW3blFtPTBibl2= M1PTWFQ5KGh? NGDiTWtFVVOR NXPCXFlFcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NI\xUWwzPDB7M{m1Oi=>
SMMC-7721 NGHLcI9CeG:ydH;zbZMhSXO|YYm= M33vb|UxKG6P M{TMWlQ5KGh? Mn;6SG1UVw>? MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> M4HETFI1ODl|OUW2
HCC-LM3 MVLGeY5kfGmxbjDBd5NigQ>? MknYOVAwOTByIH7N MW[yOEBp MWLEUXNQ M1PGfYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= NXjhU|VXOjRyOUO5OVY>
HepG2 MV\GeY5kfGmxbjDBd5NigQ>? M3HCSVUxNzFyMDDuUS=> NUHxXJlUOjRiaB?= NGO3NmdFVVOR Momx[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= NInKeYszPDB7M{m1Oi=>
SMMC-7721 NUeyZ3pkTnWwY4Tpc44hSXO|YYm= MVW1NE8yODBibl2= NVqzblloOjRiaB?= M1\PfGROW09? MWrk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi NV22cJppOjRyOUO5OVY>
HCC-LM3 NGLaVWlHfW6ldHnvckBCe3OjeR?= NIjSOII2OC9zMECgcm0> M1PvflI1KGh? NYrJW2lxTE2VTx?= NXL2dVdu\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= M2DvWFI1ODl|OUW2
HepG2 MlHKSpVv[3Srb36gRZN{[Xl? MWK1NE8yODBibl2= NXL1fJduOjRiaB?= NXTjT2RYTE2VTx?= NEHkfY1ld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MWGyOFA6Ozl3Nh?=
SMMC-7721 NGjL[HNHfW6ldHnvckBCe3OjeR?= M4fmXlUxNzFyMDDuUS=> M{LxSlI1KGh? MWPEUXNQ NEO4ZYVld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w M3LhZlI1ODl|OUW2
FaDu M{Lsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXhT|IyODEkgJXuUS=> Mli0PE8yOC9zMjDo M4rWWYRqe3CuYYnl[EBiKHOrZ37p[olk[W62IHHu[EBxem:ub37n[YQhTzJxTTDhdpJme3RiYYSgPEBidmRiMUNihKVpKHCxc4SgdoVt\WG|ZR?= NXjDWW5pOjRyMk[0PFI>
FaDu MljTSpVv[3Srb36gRZN{[Xl? NHT4eWYyODEkgJXuUS=> MmLNNk81NzhxMUKgbC=> MnH2bY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? M17ycFI1ODJ4NEiy
PC-3  MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\PVlAuOTBizszN NHTR[WMzPC92OD:3NkBp M4\T[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:yN|k6OTJzNh?=
LNCaP Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[wMVUh|ryP NXr2OGVDOjRxNEivO|IhcA>? NHnrOnpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYrqcJM6OjN7OUGyNVY>
RWPE-1  M3i5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jIZlAuOjBizszN NF\WPVIzPC92OD:3NkBp M{fEXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFjVOHUzOzl7MUKxOi=>
Capan-1 M{L0SGZ2dmO2aX;uJGF{e2G7 NEHJTVYzPS93MD:xNFAhdk1? NFn0dYM5NzJ2L{S4JIg> M4PZVmROW09? MW\kc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NW\BbottOjN7MkK4PFY>
L3.6pl Mnj1SpVv[3Srb36gRZN{[Xl? NXzyb2RLOjVxNUCvNVAxKG6P MUC4M|I1NzR6IHi= NY\3[3hTTE2VTx?= M2PCT4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= Mln1NlM6OjJ6OE[=
CFPAC-1  NEDaPZhHfW6ldHnvckBCe3OjeR?= NWjISnpQOjVxNUCvNVAxKG6P MlzqPE8zPC92ODDo NYnoXnJZTE2VTx?= M3vDNIRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NIj2SZYzOzl{Mki4Oi=>
Capan-1 NFK3NotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37yVlI2NzVyL{GwNEBvVQ>? NVTEe4t4PDhiaB?= NWjac5c6TE2VTx?= NFPYWWFz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGHTUYgzOzl{Mki4Oi=>
L3.6pl M4LK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViyOU82OC9zMECgcm0> NXHwRXA3PDhiaB?= MYrEUXNQ MlLsdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWXucox2OjN7MkK4PFY>
CFPAC-1  NV;5Nmx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXywNld5OjVxNUCvNVAxKG6P NWL3XnBnPDhiaB?= MYPEUXNQ NF3OO5Vz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFq5Uo8zOzl{Mki4Oi=>
Capan-1 M1rWc2Fxd3C2b4Ppd{BCe3OjeR?= MXSyOU82OC9zMECgcm0> NXLreXExPDhiaB?= MVjEUXNQ M1zlNIlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYiyN|kzOjh6Nh?=
L3.6pl NFP3VWVCeG:ydH;zbZMhSXO|YYm= MoXuNlUwPTBxMUCwJI5O NYrafW5nPDhiaB?= Ml;vSG1UVw>? M{W5Rolv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnLINlM6OjJ6OE[=
CFPAC-1  MnTmRZBweHSxc3nzJGF{e2G7 NGnFRY0zPS93MD:xNFAhdk1? MnHlOFghcA>? MmfQSG1UVw>? NXftc4g2cW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUiyN|kzOjh6Nh?=
HN22 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnnWIcxNTJyIH7N MmrGNlQwPDhiaB?= NIPEbINFVVOR MVfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MYGyN|g4PzJ|NR?=
HSC4  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfQcmMxNTJyIH7N M3vqdFI1NzR6IHi= NWG5e3A5TE2VTx?= NX3DRXZxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M361SFI{QDd5MkO1
HN22 M2XnV2Fxd3C2b4Ppd{BCe3OjeR?= MXywMVIxKG6P NHHaPXU1QCCq NXvDZpZ2TE2VTx?= NGHFOWZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYqyN|g4PzJ|NR?=
HSC4  NHG1VWxCeG:ydH;zbZMhSXO|YYm= MX6wMVIxKG6P MluzOFghcA>? MVTEUXNQ NYSzWVdCcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXyyN|g4PzJ|NR?=
HN22 NUDjWY52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXYRZcxNTJyIH7N MYG0PEBp NV[5e2tXTE2VTx?= M3z0fYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> MnTiNlM5Pzd{M{W=
HSC4  NE\UXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLhNE0zOCCwTR?= NXXP[GxUPDhiaB?= MYjEUXNQ MUTpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= NETRW|czOzh5N{KzOS=>
HN22 MoW3SpVv[3Srb36gRZN{[Xl? M{jOTFAuOjBibl2= NGPTWZU1QCCq MV7EUXNQ NWn4OW5se3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh NXjUWWlFOjN6N{eyN|U>
HSC4  MVfGeY5kfGmxbjDBd5NigQ>? NE[xWXkxNTJyIH7N NFXWZXk1QCCq NUO3T2loTE2VTx?= MUTzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= M3z2NFI{QDd5MkO1
Cal62 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLRcpVZUUN3ME2zN{DDuSB2IH7N NX3VT2dOOjN6MkSwOlQ>
Hth7 M4TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\aXWZKSzVyPUG1JOKyKDJibl2= M1TyT|I{QDJ2ME[0
Hth83 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHkTWM2OD1|NDFCtUA2KG6P NXj3O5RiOjN6MkSwOlQ>
C643 NHvvXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmyTWM2OD15MTFCtUAyOCCwTR?= NVW0WZBLOjN6MkSwOlQ>
SW1736 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN3INMxJFghdk1? MkPRNlM5OjRyNkS=
T241 NVvmdIdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHENGZiUUN3ME22OUDDuSB5IH7N NXzXOoVzOjN6MkSwOlQ>
T351 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76O|lDUUN3ME21NEDDuSBzMDDuUS=> NGHwb2czOzh{NEC2OC=>
BHP2-7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDpTWM2OD1|NzFCtUA3KG6P MmTPNlM5OjRyNkS=
T238 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPMUlhKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? NUK4No5QOjN6MkSwOlQ>
HCT8 NHfCW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37sNlczKGh? M1;jPWROW09? MnjUTWM2OD1zMj655qCKyrIkgJmxMlkhdk1? NXjhU2pvOjN{OUmzPFg>
H630 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm3O|IhcA>? M2[5S2ROW09? M{TZdGlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P NIDUdWUzOzJ7OUO4PC=>
cH630 5-FU-res MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3NkBp NIHPPGhFVVOR M4rvV2lEPTB;MUWuOgKBkcLz4pEJNU4zKG6P M3rMWlI{Ojl7M{i4
HCT116 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5O|IhcA>? MorCSG1UVw>? MWLJR|UxRTFyLkhihKnDueLCiUKuNkBvVQ>? MW[yN|I6QTN6OB?=
HCT116 p53−/− M4LFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzVZh3PzJiaB?= NYjXcVJWTE2VTx?= MkPTTWM2OD16LkdihKnDueLCiUGuO{BvVQ>? M4izU|I{Ojl7M{i4
dHCT116 p21−/− MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO3NkBp MXfEUXNQ MVvJR|UxRTVwOfMAjeKy6oDLMT6zJI5O NH;kZWozOzJ7OUO4PC=>
HT29 NULubY43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jCOFczKGh? MoHmSG1UVw>? NGDEd3VKSzVyPUG2MlPjiIoEsfMAjVIvOyCwTR?= MUOyN|I6QTN6OB?=
LoVo NXnWUHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULBZXJ2PzJiaB?= NInYUY9FVVOR MojETWM2OD13LkJihKnDueLCiUCuOkBvVQ>? M1G1XFI{Ojl7M{i4
RKO MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LxbFczKGh? M3TVXmROW09? M3P5RmlEPTB;Nz655qCKyrIkgJmyMlIhdk1? Mnm1NlMzQTl|OEi=
SW480 M1iwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\yPVczKGh? M37NdmROW09? M2L4eWlEPTB;MUeuOgKBkcLz4pEJNE45KG6P MWWyN|I6QTN6OB?=
eSW620 M4HI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDwVWQ3PzJiaB?= NY\EfW5kTE2VTx?= MXjJR|UxRTlwMfMAjeKy6oDLMj6xJI5O NWL3VJRzOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID